Editorial: Impact of gut probiotic metabolites on human metabolic diseases
Frontiers in Cellular and Infection Microbiology · 10.11.2026 · 16
DOI: 10.3389/fcimb.2026.1995977 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 10.11.2026. Verfasst von Senthilkumar Balakrishnan und 3 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
irritable bowel syndrome, a multifactorial disorder with abdominal pain, altered bowel habits and multifaceted interactions among the gut microbiome. The importance of evaluating probiotic efficiency at the strain level rather than at the species level, with particular emphasis on their metabolites, notably short-chain fatty acids, is highlighted. Inadequate dietary control and incomplete strain, dose, and biomarker assessments limit the application of probiotics for IBD (Mora Guzmán et al., 2026) .The effects of probiotics, Lactobacillus plantarum strain LP-115 and Bifidobacterium bifidum strain BB-06, on gut microbiota functions were investigated among liver failure cases. Rats supplemented with probiotics showed increased levels of SCFAs and decreased levels of toxic metabolites, such as ammonia. Shotgun metagenomic reconstruction of faecal DNA provided comprehensive insights into the metabolic potential of the microbiome (Luo et al., 2026).The effect of Lactobacillus rhamnosus GG, Lactobacillus plantarum, and Bifidobacterium longum on intestinal barrier function and hepatic injury in an animal model of fulminant liver failure (FLF) has been reported in this study. Probiotic treatment reduced intestinal hyperpermeability and restored tight junction integrity. In addition, probiotics reduced serum levels of alanine aminotransferase, aspartate aminotransferase, bilirubin, ammonia, oxidative stress markers and pro-inflammatory cytokines.Histopathological examination of liver tissue showed reduced hepatocellular injury and apoptosis.Probiotics may represent an effective therapeutic approach for protecting against FLF (C. Wu et al., 2026).Random forest models classified disease stages with 89.3% accuracy and identified key microbial markers, providing microbiome signatures as potential diagnostic, severity, and personalized therapeutic tools for H. pylori-related diseases. H. pylori eradication therapy along with probiotics might enhance eradication rates, reduce the side effects associated with antibiotics, help to preserve gut and oral microbiota and support their use as adjunctive therapy (X. Wu et al., 2025). Saccharomyces boulardii CNCM I-745 reduces IL-6 and TNF-α levels, increases intestinal occludin expression, and improves gut microbial composition and diversity in a rat model of sepsis. It stimulated the growth of beneficial bacteria and inhibited the growth of harmful bacteria, suggesting a potential to block disruption of the intestinal barrier and inflammation (Liu et al., 2025).In a double-blind randomized controlled trial, probiotics improved irritable bowel syndrome (IBS) symptoms by modulating increased fecal acetate, propionate, and butyrate levels; enhancing intestinal barrier integrity and tight-junction protein expression; and decreasing inflammation. Higher SCFA levels were associated with symptom improvement, highlighting the possible role of SCFAs in probiotic benefits. Overall, probiotics seem safe and effective for treating IBS through SCFA production, barrier strengthening, and anti-inflammatory effects (E. Li et al., 2025). A network metaanalysis of 29 randomized controlled trials with 4,389 patients showed that fecal microbiota transplantation (FMT) had the best improvement in bowel movements and stool consistency and acupuncture had a good clinical response. Probiotics had the lowest risk of adverse events. This study supports FMT, with or without acupuncture, as a promising treatment for functional constipation, but further high-quality studies are needed (Tan et al., 2025).The gut microbiome is a key factor influencing host energy metabolism. The review highlights the role of probiotic-fermented herbal residues in managing obesity by revealing the biological processes that improve bioactive compounds and their bioavailability by modulating the gut-liver axis. The combined herbal medicine and modern biotechnology will be a promising approach for managing metabolic disorders (Tian et al., 2026). The multi-omics approach assessed the impact of probiotic supplementation on gut microbiota composition and metabolomic profiles in women with gestational diabetes mellitus (GDM).Administration of Lactobacillus and Bifidobacterium significantly changed the gut microbiota and increased the levels of SCFAs, particularly butyrate and acetate. Gene expression analysis using RT-PCR showed a 2.5-to 1.9-fold increase in insulin receptor and AKT expression, suggesting greater insulin sensitivity; however, gut barrier genes (ZO-1 and CLDN1) also increased. Probiotic supplementation may be a non-invasive, safer therapeutic approach for GDM by improving insulin sensitivity and gut health (Su et al., 2026).The meta-analysis covers 46 randomized controlled trials with 3,580 participants with either type 1 or type 2 diabetes. Probiotic/synbiotic administration significantly decreased CRP, IL-6, and TNF-α, along with increased IL-10 and SCFA levels. Probiotic/synbiotic and SCFA supplementation may be a better diabetes care strategy (Xie et al., 2025).Another meta-analysis showed that microbial metabolites from probiotics interact with host proteins and tissue-specific pathways affecting gastrointestinal and metabolic health. Network and transcriptomic analyzes revealed important metabolite-gene relationships involving 10-hydroxy-cis-12-octadecenoic acid, glycodeoxycholic acid and N-(1-carbamoyl-2-phenyl-ethyl) butyramide. These findings identify molecular connections between microbial metabolites and host function that can inform microbiome-directed therapies and precision nutrition approaches to improve metabolic health (Yao et al., 2025).Potential host targets and biological functions of probiotic-based metabolites were identified using an integrative network-based approach based on metabolite-protein interactions and tissue-specific transcriptomics. High-degree genes including SLC27A4, LCN12 and APOD were highly expressed in gastrointestinal tract tissues, suggesting their involvement in host-microbe interactions. Metabolitespecific analysis showed different expression patterns. 10-hydroxy-cis-12-octadecenoic acid demonstrated a relationship to sialyltransferases and neuraminidase, glycodeoxycholic acid was related to bile acid metabolism and lipid transport and N-(1-carbamoyl-2-phenyl-ethyl) butyramide was related to detoxification pathways (Ma & Zhang, 2025).The systematic review and meta-analysis evaluated the effectiveness of probiotic-derived metabolitetargeted interventions on hormonal and metabolic outcomes in women with polycystic ovary syndrome (PCOS). Experimental treatments included synbiotics, probiotics, sodium butyrate, Akkermansia muciniphila, and short-chain fatty acid (SCFA) compositions, and all interventions lasted at least 8 weeks. Pooled data analysis showed a significant decrease in total testosterone, LH/FSH, fasting insulin, and HOMA-IR, with a slight increase in HDL cholesterol (Maddirevula et al., 2025).A total of 46 randomized controlled trials involving more than 12,500 pregnant women suggest that probiotic supplementation may reduce gestational weight gain and postpartum weight retention and improve fasting glucose, HOMA-IR, total cholesterol, and LDL. This study reveals that probiotics are a promising non-pharmacological strategy for improving maternal metabolic health and reducing adverse pregnancy outcomes in obese women through multiple pathways (Jia et al., 2025).A randomized double-blind and placebo-controlled trial assessed multistrain probiotics (Lactobacillus rhamnosus GG and Bifidobacterium longum) administered to 84 subjects who had closed tibial shaft fractures, through 3-dimensional microcomputed tomography (CT) measurements of BV/TV. Exploratory analyses showed that probiotics were associated with earlier weight-bearing, reduced pain at week 2, and higher RUST scores at 12 weeks. These results suggest that perioperative probiotic administration could not only promote fracture healing but also accelerate functional recovery, likely mediated by gut-bone axis-based immunomodulatory effects. Thus, probiotics can positively impact fracture care as an adjunct to standard treatment (Huang et al., 2026).Another study explored the role of probiotics in sarcopenia using data from NHANES and the UK Biobank, integrated with in vitro C2C12 myotube experiments, molecular docking, and machinelearning models. Individuals who regularly consume probiotics have higher handgrip strength and fatfree mass, and lower signs of inflammation, than those who do not. Probiotic-conditioned media greatly promoted muscle cell fusion, increased cell diameter, and increased expression of the muscle regulatory genes MyoD, Myogenin, and MyHC; it also reduced NF-κB and TNF-α while boosting PGC-1 levels. Butyrate showed strong interactions with AMPK, mTOR and NF-B. Thus, probiotics could help preserve muscle via immune responses and microbiota-controlled metabolic and muscleanabolism pathways (Wang et al., 2026).The study evaluated the impact of gut microbiome changes on postoperative recovery in postmenopausal women by examining stool samples using 16S rRNA gene sequencing and QIIME2.Analysis of alpha and beta diversity exhibited major changes in microbial composition, with a predominance of Firmicutes and Bacteroidetes, associated with improved functional outcomes and faster recovery. Conversely, Proteobacteria and Escherichia were linked to delayed healing and worse clinical outcomes. Based on microbial abundance, a random forest machine learning model achieved 85% accuracy in predicting clinical recovery, suggesting that gut microbiome signatures may serve as key biomarkers and provide a basis for microbiome-based personalized strategies to accelerate postoperative recovery and enhance long-term musculoskeletal health. Furthermore, microbiome composition correlates with various important surgical parameters such as bone healing and infection rate (Pan et al., 2026).A meta-analysis evaluated the effects of different doses and intervention durations of different probiotic strains on bone metabolism. The review states that probiotic supplementation boosts bone formation and decreases bone resorption in patients with osteoporosis. Formulations with probiotic consortia and higher doses showed significant improvements, especially in postmenopausal women, suggesting that probiotics may be a promising adjunctive approach to improve bone health. The changes observed in bone resorption markers indicate the beneficial effects of probiotics on bone health. Probiotics are not considered a primary treatment for osteoporosis, but could support maintaining bone health (Yuan et al., 2026).The human gastrointestinal tract (GIT) is colonized by a complex microbial community which plays major roles in host physiology, metabolism, immunity and neurobehavioral functions. This study highlights the bidirectional gut-brain axis, in which the gut microbiota influences neural signalling, stress responses, and emotional regulation. Dysbiosis of this gut microbiota has been linked with psychiatric, neurodevelopmental and neurodegenerative disorders such as anxiety, autism spectrum disorder, major depressive disorder, and schizophrenia. Psychobiotics are promising microbiomebased interventions for supporting mental health. These benefits may arise from modulation of neurotransmitter production, SCFA signaling, immune responses, and hypothalamic-pituitary-adrenal axis activity. FMT restores the natural gut microbiota and relieves the symptoms of mental illness via modulating inflammatory pathways. These emerging therapies, psychobiotics and FMT, may be promising strategies for managing mental health disorders (Selta et al., 2026).The study assessed the effect of washed microbiota transplantation (WMT) and investigated the changes in gut microbiota in children with autism spectrum disorder (ASD). Thirty-eight ASD children who underwent a full course of WMT from a single donor were evaluated before and 4 weeks after treatment by clinical rating scales and 16S rRNA gene sequencing. WMT significantly improved core ASD symptoms, sleep, and GI symptoms. In addition, the therapeutic effect was related to the gut microbiota of both the donor and recipient before therapy, suggesting that donor-recipient microbiota compatibility may influence the effect of WMT in ASD (Quan et al., 2026).The multi-omics study provides mechanistic evidence supporting the neuromodulatory effect of Lactobacillus rhamnosus GG and Bifidobacterium longum 1714. L. rhamnosus GG mainly boosts GABAergic and SCFA-based synaptic pathways, whereas B. longum 1714 influences the tryptophanserotonin-immune axis. Additionally, in vitro validation demonstrated increased GABA and serotonin release, reduced ROS levels, and enrichment of anti-inflammatory transcripts in EVs. These findings reveal the therapeutic potential of L. rhamnosus GG and B. longum 1714 for neurological health (Jin et al., 2026).The effect of Lactobacillus rhamnosus GG was evaluated in sepsis-induced lung injury by assessing the gut-lung axis. Probiotic supplementation in Wistar rats endangered by caecal ligation and puncture improved pulmonary function, lung histology, and respiratory parameters. Probiotic culture also restored the gut microbiota and reduced hypoxemia and inflammation. Thus, efficient therapeutic probiotics will greatly increase the success of treatment and improve the patient's quality of life and survival (Wang et al., 2026).A single-center, randomized, double-blind, placebo-controlled trial evaluated the effects of probiotic lozenges in children with adenoid hypertrophy and otitis media with effusion receiving standard nonsurgical management. Probiotic treatment significantly improved tympanogram classification compared with placebo, with favorable changes in tympanometric and audiological parameters, including DPOAE conversion. Probiotic treatment may improve auditory function by promoting probiotic colonization and inhibiting pathogens, supporting the potential of probiotic bacteria as a safe adjunct for conservative management of pediatric otitis media with effusion (Shi et al., 2026).Network pharmacology and bioinformatics analysis identified 110 gut microbiota-derived metabolites with 6,860 potential human target genes and 268 overlapping otitis media associated genes. Enrichment analyzes of these targets to inflammatory and immune pathways provided molecular evidence for microbial metabolites as candidate therapeutics (Zheng & Jin, 2025). Reanalysis of the public dataset GSE43764 identified the effect of oral Lactobacillus pentosus B240 on innate immunity against H1N1 influenza via modulation of the glutathione-ROS pathway and the macrophage type I IFN axis. Probiotic supplementation was associated with improved baseline antioxidant and oxidative stress regulatory pathways, associated with coordinated activation of GSH-ROS, Nrf2, macrophage activation and type I IFN responses. Differential and co-expression analyzes showed regulated expression of genes involved in glutathione metabolism, oxidative stress, macrophage activity, interferon signaling, and antiviral defense. Mixed probiotics significantly reduced lung damage and pathological inflammation and enhanced immune cell function and systemic immune response (Ye & Zhang, 2025).The therapeutic potential of probiotics, Lactobacillus rhamnosus, L. plantarum, and Bifidobacterium longum, along with their heat-killed preparations, extracellular vesicles, and metabolite extracts, to control HPV-associated head and neck cancer is demonstrated using microbiome, immunological, and computational approaches. Probiotic treatment improved immune regulation and epithelial barrier function and decreased cancer cell viability by inducing apoptosis. Their therapeutic potential was also supported by increased caspase activity and immunoregulatory cytokines. These results suggest that live probiotic cultures and their various forms and metabolites could be promising adjunctive therapies for HPV-associated head and neck cancer (Jiang et al., 2026).A randomized controlled trial (RCT) investigated the effects of comprehensive nursing care combined with probiotic intervention on improving gut health in patients with malignancies. After 8 weeks of intervention, the observation group had better gastrointestinal function and nutritional status, reduced non-infectious complications and improved quality of life among patients undergoing chemotherapy.This study found therapeutic value in probiotics combined with comprehensive nursing care for patients with gastrointestinal malignancies (Huang et al., 2026).The retrospective study investigated how a probiotic-rich diet combined with an enhanced recovery after surgery (ERAS) nursing pathway, affects postoperative recovery in patients with laryngeal cancer.The treatment with probiotic formulation containing Lactobacillus acidophilus LA-5, Bifidobacterium animalis subsp. Lactis BB12 led to higher recovery rates in energy and protein intake in the early postoperative phase through the gastrointestinal tract. Inflammatory markers CRP, IL-6, and leukocyte count had increased, and albumin and prealbumin levels had declined. The probability of complications, including pneumonia, wound infection and pharyngocutaneous fistula, was much reduced. Hospital stay and antibiotic use were reduced (Wei et al., 2025).In this meta-analysis of 18 randomized controlled trials with 1,246 women with endometrial cancer (EC), probiotics increased gut microbiota diversity, increased beneficial bacteria, and reduced gastrointestinal complications. Probiotics also improved well-being and reduced IL-6 and TNF-α levels. Multi-strain formulations, higher doses (≥10¹⁰ CFU/day) and longer interventions had greater benefits, supporting probiotics as a potential adjunctive therapy (Chen et al., 2025).This review explores the significant role of Akkermansia muciniphila, an important gut commensal, in maintaining gut immune homeostasis and metabolic balance. The molecular mechanisms underlying the anti-inflammatory effects of A. muciniphila involve intestinal barrier enhancement, immune modulation, metabolite-mediated signaling and reshaping the gut microbiota. This review also notes that pasteurized preparations and bioactive metabolites can have therapeutic effects alongside live bacterial cultures (Xie et al., 2026). This review highlights the phenylketonuria pathophysiology, gut probiotics, phenylalanine amino acid metabolism, and the therapeutic potential of probiotics. Pre-and probiotic-based approaches could benefit phenylketonuria treatment by increasing microbial diversity and making the microbiome more resilient, enabling the intestine to resist disturbances and prevent losses in functional diversity (Kalla Veedu et al., 2025).Though gut microbiome and their metabolites ae gaining more attention and popularity, the interpretation and therapeutic strategy of the available data are limited due to less availability of clinical translations. Molecular docking, computational projections, and in vitro investigations provide mechanistic insights, but they do not adequately replicate physiological circumstances or prove clinical relevance. Such in silico studies require experimental validation for identified biomarkers and predicted metabolite-protein interactions. Clinical consequences are not always causally linked to changes in microbial abundance or metabolite concentrations. It is yet unclear how microbial metabolites, live probiotics, microbial consortia, and host responses relate to one another. Furthermore, conclusions drawn from certain strains, formulations and disease models cannot be applied to all probiotic treatments. In this research topic, the published in vitro and in silico studies indicate potential probiotic activities, metabolites, host targets and biological pathways but cannot be used to establish a therapeutic effi
Zitieren
APA
Balakrishnan, S., Selvankumar, T., Kandasamy, S., & Duraisamy, S. (2026). Editorial: Impact of gut probiotic metabolites on human metabolic diseases. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1995977
Vancouver
Balakrishnan S, Selvankumar T, Kandasamy S, Duraisamy S. Editorial: Impact of gut probiotic metabolites on human metabolic diseases. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1995977
BibTeX
@article{Balakrishnan2026,
author = {Balakrishnan, Senthilkumar and Selvankumar, Thangaswamy and Kandasamy, Selvam and Duraisamy, Senbagam},
title = {Editorial: Impact of gut probiotic metabolites on human metabolic diseases},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1995977}
}
EUVIMED